The Biopharma A List: Taking The Pulse of Newco Creation In 2024

 
• By Amanda Micklus

The landscape for overall private biotech financing in 2024 featured investors who were interested in funding new developments – if Big Pharma was willing to pay up eventually in partnerships and M&A – but also reluctance as the industry faced macroeconomic and regulatory uncertainties.

(Shutterstock)

A key indicator of the strength of the biopharma industry is the health of new company creation. By reviewing Series A financing announced in 2024 as a proxy, In Vivo once again takes measurement of start-up activity and investor appetite for new and exciting science.

First-time financing by start-ups typically represents a strong proportion of overall venture capital (VC) funding. Since 2017, that percentage has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

More from In Vivo